



## Kyverna Therapeutics to Present at Upcoming Investor Conferences in September

August 25, 2025

EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the following upcoming conferences:

### **2025 Wells Fargo Healthcare Conference**

Format: Fireside Chat

Date: Wednesday, September 3<sup>rd</sup>, 2025

Time: 11:00 a.m. ET

### **Morgan Stanley 23<sup>rd</sup> Annual Global Healthcare Conference**

Format: Fireside Chat

Date: Monday, September 8<sup>th</sup>, 2025

Time: 4:05 p.m. ET

### **H.C. Wainwright 27<sup>th</sup> Annual Global Investment Conference**

Format: Fireside Chat

Date: Tuesday, September 9<sup>th</sup>, 2025

Time: 11:00 a.m. ET

Live webcasts of the presentations may be accessed via the Investors section of the Kyverna website at [ir.kyvernatx.com](http://ir.kyvernatx.com). Archived replays of all events will be available on the website for approximately 90 days following the conference.

### **About Kyverna Therapeutics**

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on liberating patients through the curative potential of cell therapy. Kyverna's lead CAR T-cell therapy candidate, KYV-101, is advancing through late-stage clinical development with registrational trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase 1/2 trials for patients with lupus nephritis. The Company is also harnessing other KYSA trials and investigator-initiated trials, including in multiple sclerosis and rheumatoid arthritis, to inform the next priority indications for the Company to advance into late-stage development. Additionally, its pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats, including efficiently expanding into broader autoimmune indications and the potential to increase patient reach with KYV-102 using its proprietary whole blood rapid manufacturing process. For more information, please visit <https://kyvernatx.com>.

### **Contacts:**

Investors: [InvestorRelations@kyvernatx.com](mailto:InvestorRelations@kyvernatx.com)

Media: [media@kyvernatx.com](mailto:media@kyvernatx.com)